Hello and welcome to the ResMed Second Quarter Fiscal Year 2023 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Amy Wakeham, Vice President, Investor Relations and Corporate Communications. Amy, please go ahead.

Great. Thank you, Kevin. Hi, everyone. Happy new year and welcome to ResMed's second quarter fiscal year 2023 earnings call. Thanks for joining us. This call is being webcast live and the replay will be available on the Investor Relations section of our corporate website later today, along with a copy of the earnings press release and the presentation, both of which are available now. Joining me on the call today are Chief Executive Officer and Chairman, Mick Farrell; and Chief Financial Officer, Brett Sandercock. Mick will provide a brief high-level overview of our financial results, review our progress towards our ResMed's 2025 strategic goals, and discuss our progress as we continue to navigate the ongoing macro industry and supply chain challenges. Brett will then review our financial results in more detail. And we'll then move into the Q&A portion of our call. During the Q&A session, Mick and Brett will be joined by Rob Douglas, President and Chief Operating Officer; and David Pendarvis, Chief Administrative Officer and Global General Counsel. During today's call, we will discuss several non-GAAP measures. For a reconciliation of the non-GAAP measures, please review the supporting schedules in today's earnings press release. And as a reminder, our discussion today will include some forward-looking statements, including, but not limited to, expectations about our future operating and financial performance. We do believe these statements are based on reasonable assumptions. However, our actual results may differ. Please review our SEC filings for a complete discussion of the risk factors that could affect our actual results to differ materially from any forward-looking statements made today. I'd like to now turn the call over to Mick.

Thanks Amy and Kevin and thank you to all of our stakeholders for joining us today as we review results for the December quarter, our second quarter of fiscal year 2023. Our financial results reflect solid performance across our entire business, once again driven by strong sales growth in the Americas region as we were able to significantly increase both production and delivery of flow-generator devices. We're seeing ongoing high demand for our sleep and respiratory care devices worldwide and we're making steady progress, working with our suppliers to continue to increase our production to ultimately meet the needs of all customers and especially patients. Our mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness of the importance and need for respiratory hygiene and respiratory health. ReSupply programs in the US continued to drive solid, ongoing sustained market mask growth catalyzed somewhat by the end of calendar year deductible momentum in the US geography. Mask sales across Europe, Asia, and the rest of world also improved, driven by increased new patient setups as connected device supply increased. Our teams worked incredibly hard to achieve these extraordinary numbers in the face of an ongoing industry supply chain constrained market. We see the supply environment improving every week, every month, and every quarter, and our access to the specific electronic components we need has increased. We are confident in our ability to fulfill all customer demand before the end of calendar year 2023 and we expect to see steady ongoing incremental device revenue growth in the third and fourth quarters of our fiscal year 2023. Customer acceptance of our reengineered AirSense 10 Card-to-Cloud device remained strong during the second quarter, particularly in the United States geography. As we increase the volume of fully connected AirSense 10 and fully…

Great. Thanks, Mick. In my remarks today, I will provide an overview of our results for the second quarter of fiscal year 2023. Unless noted, all comparisons are to the prior year quarter. We had strong financial performance in Q2. Group revenue was $1.03 billion, an increase of 16%. In constant currency terms, revenue increased by 20%. Revenue growth reflected increased demand for our sleep products across our portfolio and ongoing increased device demand generated by our competitor’s product recall. Year-on-year movements in foreign currencies, in particular, the weaker euro negatively impacted revenue by approximately $36 million this quarter. As mentioned, we closed the MEDIFOX DAN acquisition on November 21, 2022 and accordingly, we have recognized MEDIFOX DAN revenue of $10.7 million in our Q2 FY 2023 results from this date. While we continue to experience ongoing challenges in securing sufficient electronic components to meet market demand, we are now seeing a more predictable and improving supply chain environment. We expect to continue to deliver sequentially higher quarterly device revenue through the balance of fiscal year 2023. Looking at our geographic revenue distribution and excluding revenue from our Software-as-a-Service business, sales in US, Canada, and Latin America countries increased by 26%. Sales in Europe, Asia, and other markets increased by 8% in constant currency terms. Our product segment, globally, in constant currency terms, device sales increased by 25%, while masks and others sales increased by 13%. Breaking it down by regional areas, device sales in the US, Canada, and Latin America increased by 41% as we benefited from incremental revenue derived from the introduction of the Card-to-Cloud device and improving availability of our connected devices. Masks and other sales increased by 11%, reflecting solid ReSupply revenue. In Europe, Asia, and other markets, device sales increased by 5% in constant currency…

Great, thanks, Brett and thanks Mick. Kevin, I'd like to now turn the call back over to you to provide the instructions and then run the Q&A portion of our call.

Certainly. We'll now be conducting a question-and-answer session. [Operator Instructions] Our first question is coming from Chris Cooper from Goldman Sachs. Your line is now live.

Thanks. Good morning -- good afternoon. So, good to hear the fully connected AirSense 10 is now off allocation. Can I ask what happens with the C2Cs that have effectively now I presume surplus to requirements? And are there any sort of impacts on pricing or inventory valuation we need to think about in the second half?

Thanks for the question, Chris and it's a good one. Obviously, we're thrilled to have AirSense 10 fully connected now, unconstrained in the US geography. As you know, we operate in 140 countries worldwide. The AirSense 10 Card-to-Cloud inventory, we're working our way through that and it actually is moving very quickly. I'd state it this way that we've got the number one device in the market, which is the AirSense 11 fully connected in terms of customer ratings. We also have the number two device in the market, which is the AirSense 10 fully connected. But then we have the number three device the third best device in the market, which is the AirSense 10 Card-to-Cloud, I believe that's better than the tier 2, 3, 4 competitors that are in the market. And so we've got the number one, two, and three device there and we're selling them and different customers want different things. And certainly, the AirSense 11 fully connected is at a price premium. But we'll start to see, I think us work through all of our inventory, the excess patient demand is still there globally. And I think we'll be there for a period of time, even after one of our competitors looks like they may come back into the market, hopefully sometime this this calendar year so that we can get our mask attachment rates on to them. But yes, Chris, we expect to work through all that AirSense 10 Card-to-Cloud inventory. Good question.

Thank you. Our next question is coming from Suraj Kalia from Oppenheimer. Your line is now live.

Mick, can you hear me all right?

Got you loud and clear, Suraj.

Congrats on a great quarter. Hey, Mick, maybe I'm just trying to thread the needle here, but love to get some extra color. I heard you say by 2025, 250 million lives, that's the plan. If I use where you are currently, let's say 150 million, just rounding it off, that's a 70% almost jump in patient covered life -- covered by CPAP. How should I think about the implied guide? Am I jumping the gun here? Or are you sort of telegraphing you'll should be in a position for the next three years deliver about 17%, 18% CAGR? Thank you.

Suraj, it's a great question and how we measure the lives changed is a pretty simple formula includes the CPAPs, APAPs, bi-level devices. But it also includes full mask systems, which you know, the sort of linear growth, if you like of the devices and some slight exponential growth of the mask systems because of replenishment rates and repeat customers coming back. But it also includes patients' lives touched through digital health. So, whether it's a Brightree patient who gets access to their device or other HME equipment, whether it's a patient in COPD medicines that gets an app that reminds them to take their medicine on a Propeller, or a patient that has a life support ventilator that gets a digital health reminder to get replenishment. And so combining all those impacts on a life. And the way I look at it is a life is changed as much by a brand new device arriving in their house as it is by an app that helps them take a medicine that keeps them out-of-hospital. So, that's how we sort of look at lives change. Yes, 150 million calendar year 2023, you got it, right. I mean, you got the math, the mathematics there is the CAGR is 17.5% volume growth of the lives that we touch over the next three calendar years through 2025 and we're going to do that. We're going to get more and more patients on CPAPs, APAPs, bi-levels, more and more on ReSupply and masks systems, and then more and more on our digital health platforms. And we've got -- it's a lofty goal and it's a stretch goal, but we believe we can get there and change 250 million lives by 2025. Thanks Suraj. Great question.

Thank you. Our next question is coming from Matthew Mishan from KeyBanc Capital Markets. Your line is now live.

Hey. Good afternoon, Mick. Just a quick question on the gross margins. Just how has the productivity of manufacturing and shipping improved over the last few months? Are you guys still working through, like high-cost inventory? How much spot buying is there? And then is sort of the decrease in gross margins -- slight decrease in gross margin, mainly on the mix of devices versus masks and accessories?

Yes, Matt, I'll start and then I'll hand to Rob Douglas, our President and Chief Operating Officer to cover in detail. But just at the start, yes, there was a sequential decrease in gross margin. One way, Matt, I could have avoided that is tell the team don't sell all those CPAPs and APAPs, to create, right because it was great gross profit dollars to the business and was great to change a patient's life by a new device, but I could have get my GM 70, 80 basis points up by saying slow down those CPAP and APAP sales. Of course, we didn't do that. The right thing is the humanitarian aspect to get those devices that we pivoted, our supply chain reengineered and redesigned to get them to market and you saw extraordinary growth, 41% growth in our US-based device market. Now, that's not our highest gross margin, its diluted to GM percentage, but it's contributory and positive to gross profit dollars. And so it's good for patients, and it's good for our stakeholders. So, that's what we did. But Rob, yes, some a really good question -- first part of the question.

Yes, Matt, thanks for question. There's lots of factors in that gross margin and you're asking specifically about productivity and productivity improvements. We've done a whole lot of work around volume improvements and really driving volume and all of our discussions with suppliers have been increasing volume and reliability of delivery. Our normal settings in normal world is we have a long-term outlook volume commitment and we're looking at optimization and pricing improvements and things like that. Those activities have pretty well been on hold while we've been doing these -- this sort of real scramble that drive volumes. Freights a similar situation, although we are seeing freights probably going to improve faster than some of these other costs that were in there. But totally in terms of our supply chain culture, we absolutely will be aiming to go back to our continuous improvement situation where we have a really strong volume leverage gain. We continue to drive the volumes in a systematic way and we use that to drive productivity and drive cost out of the system.

Thank you. Our next question is coming from Steve Wheen from Jarden. Your line is now live.

Yes, thanks Mick. I just wanted to follow up on that gross margin question. In the previous quarter, I think it was -- Brett was talking to the efficiencies that you're achieving through doing more volume, was -- the margin benefit from that efficiency was sitting in your inventory balance and that's obviously been building and built again this quarter. I'm just interested is that still the case that when that inventory comes off the balance sheet, you should automatically start to see the efficiency gains that you've been able to achieve to-date?

Brett, do you want to have a first go of that question?

Yes, Mick thanks. So, Steve, yes, I mean, that's -- what we're doing -- I mean -- I think Rob articulated really, at the moment, we're optimizing for delivery rather than efficiency and we got things like we're running the three platforms at the moment. So, I'm really focused on delivering devices to patients. So, that's having an impact. The big one is work through inventory or the wash-through is the freight cost. So, we're seeing some reduction in freight costs. But that's not manifested in our P&L, yet, that's one for the Q3, Q4. So, there will be some benefits that starts wash through into Q3 and Q4 that we're not seeing it that's currently still in inventory. But on the efficiency side, we're really -- we will get there, but we're optimizing on delivery for the moment. But I think as we work through the fiscal, we'll be in a much better position to drive on efficiency measures.

I’d just pile on there that you look at Brett's guidance, nice conservative guidance is that our gross margin will be sort of steady as we go forward. I look on this and say, I think there's some upside. As we start to see mask rates start to improve, we saw 13% constant currency growth in masks during the quarter. I think, yes, as Brett said, the freight costs will wash through the inventory. And we're getting great scale from the biggest respiratory medical manufacturing plant in the planet, there in Singapore and the efficiency we've got a well above any competitor and we're doing really well on that and I think that'll come through. And then in addition to that, you'll get some upside from MEDIFOX DAN, which is accretive to revenue, gross margin, and EPS, as Brett said, throughout fiscal and beyond. So, that would be my guidance there as well, Steve. Thanks for the question.

Thank you. Our next question is coming from David Bailey from Macquarie. Your line is now live.

Yes, thanks very much. Morning Mick and Brett. Just got a question on new patient growth. Just thinking about patients who have been prescribed the device and waiting and also those yet to be diagnosed, just wondering if you could compare and contrast the US and rest of world? And then some comments on what you think it means for industry device growth for fiscal 2023 and 2024 relative to our historical growth rates?

David, that's a great question. It's actually the answer. We could take the whole rest of the Q&A session to go through it because it's what we do is trying to reach out to the 936 million people in our core market that suffocate every night with sleep apnea around the world and we're laser-focused on it. As you saw, we delivered very strongly on those new patient setups 41% growth of devices in US, Canada, Latin America and we turned to positive there in Europe, Asia, and other. And what I can tell you is we're really working through that excess patient demand. Those numbers will tell you we're working faster through that excess demand in the US and getting closer to a state you get a prescription and you'll get a device in days or weeks versus it gone up to months there at the peak of the crisis. And I think if you look across the other 140 countries we sell into, every country is different. We've got to get the regulatory approval for AirSense 11 there. We've got to work our way through, but we're going step-by-step on that journey. And so as I look at this excess patient demand, I made the comment there in my prep remarks, I think we will get to all of our customers' demand before the end of this calendar year and that tells you our confidence in increased supply and our ability to meet that need, and we're laser-focused on that humanitarian emergency of patients waiting too long for therapy and we just don't want that you suffocate. This is a case of life and death; we've got the data to show that. We want your path to therapy to be expedited. And in addition to that, the final thing I'll say is that we are looking at our patient demand generation activities that have been on hold these last 18 months. And I'm looking at our models in Australia, New Zealand, Korea, Japan, Singapore, UK, and beyond where we have these omnichannel markets availability to contact consumers or sleep concern consumers directly and get them into the funnel. And here in the US, we have direct models and also our joint venture there with Verily and Primasun that we've done some really good demand gen tests and a number of cities just waiting for me to fire the starting gun for that team. And we're getting very close to firing that starting gun. So, we have a smooth flow of -- from excess patient demand to now patient demand generation to continue our growth trajectory.

Thank you. Our next question is coming from Mike Matson from Needham & Company. Your line is now live.

Yes, thanks for taking my questions. I guess, Mick, I think you mentioned high flow therapy in your prepared remarks. I just wanted to get an update on kind of where things stand with commercializing that? And maybe talk about the -- just the market opportunity there? Thanks.

Yes. Look, it's a great question, Mike. And our long-term goals there in 2025, a number of those 250 million lives are going to change in 2025 will be patients with neuromuscular disease or chronic obstructive pulmonary disease. And two of those great therapies, high flow therapy in the home, I want to be very specific, it's been used in the hospital during the pandemic. High flow therapy in the home, we see as a huge opportunity, probably 10 times the size of our ventilation market in COPD is available for home therapy, HFT therapy. And then Propeller, yes, early days and the pilots are going well. We're integrated to the payer provider EHR systems, which gives us the credibility now to go from pilots to start to scale some payer providers, particularly in the US geography. But Rob, any further details on our work on HFT and cloud connected inhalers for Mike there?

Yes, Mike. We're pretty excited about this. It's a long-term project though, but as Mick said, we view this as a very large potential market, very significantly larger than some of our other respiratory care markets. And we believe that we're running tests -- we're really focusing on its complementariness with home oxygen therapy that is you'll get much better outcomes if you add this in. And we're working hard on all of the market access and evidence generation programs to do that. Now, most of those programs are buying either RCTs or real-world evidence trials. So, we're sort of in limited market release at the moment in specific markets where we're making these claims. But as that evidence evolves and we generate it and take it to the -- to payers and standard setting organizations, we see this is going to be a very strong market for us, but it is a multiyear project.

Thank you. Our next question is coming from Craig Wong-Pan from RBC. Your line is now live.

Thank you. Just a question on the SaaS business. The 7% organic growth that you mentioned, I was wondering if much of that was benefiting from price increases or if the price increases you started through the quarter have a bigger benefit to come through in future periods?

Yes, Craig, thanks for the question. No, that doesn't include a whole lot of price increases. In fact, we put price increases on hold during the COVID pandemic in some of our SaaS businesses and so we probably are changing to the area of price increases as we go forward. We've gone from pandemic to endemic, so that will happen and then flow out over the coming 12, 24 months. I'm really excited. We're looking at that domestic SaaS business in the worst of COVID getting down to low single-digits. We moved to mid-single-digits. And then Bobby, who's President of that division and his team have really accelerated that organic growth to 7% -- 8% last quarter, 7% this quarter, and so that high single-digits organic growth. And actually, we see upside from that in the organic, if you think about it, Brightree, MatrixCare, and Citus Health path. So, we see opportunities to move that up. And then when you add on MEDIFOX DAN and its capabilities, I think the combined business, obviously, the next four quarters, we'll call out the inorganic part will be double-digits on the inorganic, of course. But even going forward, as we look out towards 2025, we see opportunities for high single-digit and even low double-digit growth across that combined business as we lap the acquisition. So, really good growth there. Price increases will be a part of that going forward, but they weren't historically, to answer your question directly.

Thank you. Our next question is coming from Sean Laaman from Morgan Stanley. Your line is now live.

Good morning Mick, hope you well. Mick my question is do you have enough visibility on the component pipeline to ascertain when you might be able to provide direct cloud connected devices in those markets that have an aversion to the Card-to-Cloud?

Yes, Sean, I hope your Sydney morning is going well day after Australia Day. Look, the way we're looking at this is we've got 140 countries. We've got a very complex supply logistics program to get the patients minimize the time from prescription to therapy across all those markets, but it's a complex equation. The good news is we are seeing supply of those rate limited semiconductors for communications. The 3G, 4G, 5G chips are starting to see supply come back. The microprocessors, the next rate limited step are starting to increase and so we're seeing our path through this. And you saw in the quarter, we were able to deliver incredibly strongly on that, and we're off allocation for the AirSense 10 100% connected. Look, I'd love to tell you, we've got a very complex jigsaw puzzle here. I'd love to tell you it will be off allocation on AirSense 11 in all of our markets. It's just not going to happen in the short-term. But as we go through this year, we'll update you as we go off allocation and it will happen market-by-market geography-by-geography. Rob, did I miss anything there?

The only other comment, Sean, is some of this is driven by regulatory requirements around getting approvals and validations and also, several of these markets have different components that they need. So, they're different validation and engineering projects to do it. And we just have to sequence that through our prioritization process as well. So, that's actually true with all product launches.

Yes, and the good news is it's not our first rodeo. We've done this launch platforms in 140 countries many times before, and we're back to our sort of meat and potatoes here. This is what we do all day every day. And going off supply chain constraints over the calendar year will be fantastic for us to be able to then just go back to what we do, which is helping people sleep better, breathe better, and live better lives outside hospital care. Thanks for the question Sean.

Thank you. Our next question is coming from Margaret Kaczor from William Blair. Your line is now live.

Hi, good afternoon guys. Thanks for taking the questions. Good morning to Brett. I wanted to follow-up on the growth drivers as we think about this and next year, because I'm hearing there's patient backlog, obviously, there's core market demand generation that will start to pick up. And then from our perspective, we look at RePAPs as well. So, how do you layer those together over what time period? How much growth could you handle? And then maybe specific to RePAPs, since we haven't talked that much about them on this call, where have they been in the last two years? And when should they return to be a bigger piece of the mix itself? Thanks.

Yes. Thanks Margaret. It's a great question and it's one we're thinking about a lot here. And we're thinking about all three prongs that you talked about. The first one, excess patient demand, how do we work through that. US, we're getting close to really working through it. We've got 140 other countries. And to Rob's point, it's a complex equation to get the supply chain and deliver in all 140, but we're working through that. Secondly, demand generation, yes, where we have omnichannel and have really established social media presences and abilities to drive demand gen, we'll be starting to turn those on country-by-country. And then thirdly, RePAPs, to your point, the last two and a half, three years of COVID crisis, pandemic crisis, competitor recall crisis, we have not turned the knob on RePAP. And in fact, we know our customers have been holding back when they're supply chain constrained on contacting patients who reach that three-year, five-year post-warranty, you're ready for a new device on insurance and/or patient making the call. So, I think all three of those are going to be applied in all 50 states here in the US and in all 140 countries worldwide. We do have scenarios and plans, I'm not going to detail them here on this call, but I can tell you that we expect to see steady growth throughout our market and we're going to drive that. And we're going to make sure that patients waiting lists are not long. We're not going to turn the needles until we're ready to get there in supply. I'm just happy we're having this conversation this quarter and it's so much better than the last eight quarters that we're talking about demand gen and driving RePAPs, because that's what we've done for 33.5 years in the business and it's what we love doing and we're going to do more of it.

Thank you. Our next question today is coming from Matt Taylor from Jefferies. Your line is now live.

Great. Thank you for taking the question and good morning and good evening. I had a follow-up on that question. I guess I just wanted to understand what are your expectations if and when your competitor does come back? I mean, presumably, there could be some, I guess, impact on flow gens that would create pressure, but maybe you get some pickup in the mask. Could you characterize how quickly you would expect things to change dynamically in both directions? And then how much juice can you actually get out of the demand creation and ReSupply to backfill or you, kind of, increase growth? What are your pilot programs or places where you've done that telling you about how much of a quantitative pickup you can get?

Yes. Thanks for the question Matt. I'll start and hand to Rob for further detail because it is a really important area for us. Look, if you think about -- our competitor has been out on the market for 18 months and who knows. They've got to -- we'll find out probably later this week, they got an earnings call, maybe they'll tell us what's happened at the consent decree and give us some timing. Frankly, give the market some time it'd be good. We've run scenarios, they come back Monday February 1, July 1, we've also run scenarios that it's January 1, 2024. And actually, in all those scenarios, ResMed grows and ResMed does really well, and ResMed does a really good job of taking care of the unmet patient need. So, if they come back earlier, come back Monday, we get a 60% plus or minus attach rate of our masks. So, we get good GM contribution, great patient care in terms of the best masks in the planet going to them, and we're able to drive that. Now, they'll be starting from 0%, new patient share, they're going to able to go and fight account-by-account. And they won't be fighting against ResMed out the gate. They'll be fighting against the Tier 2, 3, and 4 players who have come in to fill that part of the equation and they're doing an okay job. And so they have to fight against the okay players. Then they have to fight against us, the market leader. But I look forward to them coming back actually in terms of the mask side of the business, it will be really good. The scenario where it's further out, it's later this calendar year or early next calendar year or beyond. We're okay with that too because we're ramping up our supply, and we're going to get closer and closer to meet all of customer demand in this. So, frankly, it's not irrelevant, but it's not a big perturbation of our long-term strategy and our long-term business. And we've got the scenarios and the little pivots that we need to have more masks or more demand gen in the different scenarios. So, I think investors and some analysts are thinking more about this -- are worried -- more worried about this than we are because we thought so much about it and have the scenarios and the playbook ready for all three of those scenarios and 2020 beyond. I look forward to this sort of people calling a binary. I see there's a mild perturbation of the Monte Carlo sim that really doesn't change in the long-term outcomes for ResMed and our patients is not changed in any of those scenarios. But Rob, any further detail for Matt here?

Yes, Matt the only other thing I'd add is we sort of think of sort of market growth rate in terms of the patient lifetime journey through this condition -- terrible condition, very serious and the biggest problem is awareness. And so you start off with how do you become aware of it. Does your primary care know to refer you to a sleep specialist? Can that specialist refer you to either home or lab testing? And then do you get a referral to a provider who's got the capacity to look after you. And basically, staff capacity is even a big issue for them. And so -- and then will that provide a look after long-term and keep the ReSupply programs. And our solutions are across all of those, but there's bottlenecks in all of those parts of the patient lifetime -- patient journey, if you like. And as I say, we're providing solutions across that and incrementally driving improvements across all of those. So, that provides a really good long-term outlook for steady growth in the business, as Mick was saying.

Thank you. Our next question is coming from Michael Polark from Wolfe Research. Your line is now live.

Hey, good afternoon. Two quick ones if I can sneak them in. Is there a vision or strategy to convert Card-to-Cloud products to connected solutions over time? Or is the base case to lead those units that have gone into the market over the last year or so, as is? And then the second quick one is MEDIFOX DAN, the gross margin on that revenue ballpark, can you share what that is? Thank you so much.

Thanks Mike and cheeky sneaking in two questions, but I'll answer both for sure. Card-to-Cloud, as those devices -- as those AirSense 10 Card-to-Cloud devices reach their either warranty period or payer allotted period at which a patient can get another device allocated to them, which is usually in the three years or five years, normally time horizon, those patients will get the opportunity to upgrade their devices from an AirSense 10 Card-to-Cloud to presumably an AirSense 11 device. And look, the first 26 years of ResMed's existence, we had, firstly, non-connected and then Card-to-Cloud pager-type technologies sort of sneaker-net. It works. It can get you there. It's not as optimal. It doesn’t get that sort of patient engagement on myAir and all the abilities that we can get to that 87% adherence, but it's darn good therapy. It's the smallest, quietest, the most comfortable therapy. And with the Card-to-Cloud, our HME -- mostly sold in the US, HME customers have done this for years and the data go to the cloud, and so the doctor doesn't see much difference because the doctor is seeing all the data in AirView on Card-to-Cloud and directly connected and so actually able to drive really good care with those patients. So, it will be a bolus of patients over that sort of 12-month period. And we've had, I would say, some pretty good success in humanitarian aid really and showing that ResMed isn't just going to stick to a strategy. It's going to say, if we need to pivot tactically to take care of patients, we'll do it and we'll take care of them long-term. But there will be a bolus of patients, I think, jumping at the front of RePAP in a couple of years who want to get the latest and greatest technology and some on consumer pay markets might go quicker. The second question around gross margin. Yes, look, MEDIFOX DAN accretive to our group gross margin. I'm not going to quantify it exactly, but that's why I said you're going to see, I think, some upside to our GM as we go through the fiscal year, including MEDIFOX DAN. It's accretive to revenue, gross margin percentage, but also NOP dollars and our EPS performance over the fiscal and beyond. Thanks for the questions Mike.

Thank you. Next question is coming from Saul Hadassin from Barrenjoey Capital. Your line is now live.

Good afternoon and good morning. Thanks for taking my question. Mick, just a quick one. Just the US flow generator growth rate of 41%, obviously, very strong. Just wondering if you can give us any color as to within that, how much was volume versus price and also mix?

Yes, Saul, look, it's a great question. We don't split out our details on price. But I can give some sort of general color and maybe, Rob, Brett, maybe you want to add a little bit on for Saul to the color that we can provide. Competitive dynamics are very tight. Look, we were very open that we had a surcharge that we put the start of last year around the freight costs that were incredibly high, $12 and EUR12 across all devices and so on. We will start to actually take that away to get customer-by-customer and appropriately as we go through the year. And as we actually see -- to Rob's point earlier, as we see those freight costs come through our inventory, they don't just come in a spot change, it takes time for the COGS reduction there to come through. But in terms of that 41%, I can say it was materially improved by the AirSense 10 Card-to-Cloud and was able to get those devices there. But our ability, I think, also as we have started this quarter to turn AirSense 10 fully connected off-constraint, I think will continue to be a nice tailwind for our business there. But Brett, I'll hand to you for any further color we can provide to Saul to help on his modeling on this great US flow generator growth.

Yes. Thanks Mick. I mean the only thing I'd add, Saul, is that we -- it was really the sleep devices or APAP devices are really strong as we got device availability that went straight into the market. So, that was really kind of driving that, which is obviously higher volume devices than, say, bi-levels, for example. So, that did definitely play a big part in that revenue growth.

Thank you. Next question is coming from David Low from JPMorgan. Your line is now live.

Thanks so much. Just a quick one. Mick you talked about being unconstrained on supply by the end of the calendar year and then I think to Sean's question, you talked about different markets and regulatory approvals. So, the question I've got is will the AirSense 11 be unconstrained more quickly in the US? And can you give us any sort of sense as to when you expect that will be the case?

Yes. Thanks for the question David. Yes, clearly, AirSense 10 fully connected will be unconstrained first just because that platform has been in the market for a long period of time. We've got all the inventory, all the capabilities to drive it, and it's regulatory approved in virtually every market, 140 around the world. And so it's just much easier to turn that off-constraint and get it moving first. But yes, to your point, the smaller, the quieter, the more comfortable and the most connected and most clever device is the AirSense 11. As we get regulatory approvals and we're going country-by-country on this. As we said, we just got Japan during the last quarter and we're going to go country-by-country on this, when we get regulatory approvals and as we get supply starting to improve on those components, we can really ramp that up with all its great technology and really good cost advantages and patient-friendly advantages. It's got coaching capabilities and interaction with the patient on the screen that's interactive and can do some really good over-the-air upgrades, but also over-the-air interactions with physicians and its connectivity to myAir, 55%. I mean almost vast majority of patients are being offered and almost for all them are saying, yes, I want to see my data every day and get a myAir score. So, it will go faster and less constrained in those markets where it has approval. I'm not going to predict the exact date that that will happen because we've got scenarios around that. But I think we will start to see that go off-constraints before the end of the calendar year because that's when we're going to be able to meet all the customer demand, which is our goal and with on a fast-track to do it this calendar year. Rob, what did I miss there on David's question?

The only other thing is, David, it's been really important for us to be able to supply those two platforms. It's been a great thing for us to have sort of a double. Basically, we've got so much extra capability and capacity because we've got two platform lines designed for the market.

Thank you. Next question is coming from Dan Hurren from MST Macquarie -- I'm sorry Marquee. Your line is now live.

Hi, good morning everyone. Thanks for taking the question. Look, it's pretty clear that a lot of the growth is now coming from products that have been reengineered and didn't really even exist in their current form a little while ago. So, -- and we've seen AirSense 10 connected as you're talking about launch with different parts and alternate supplies and so forth. But we've also seen some early regulatory approvals for an AirSense 11 with apparently different communication chipset. Is there any reason why that product couldn’t launch within the next few months as you've seen roughly the same time line between approval and launch for something like the AirSense 10 connected?

Yes. Thanks Dan. And clearly, you're very diligent looking at FDA and different regulatory approvals around the world. Look, what I'll say to this is that the AirSense 10 Card-to-Cloud was a reengineered re-pivoted device, absolutely. And the AirSense 10 fully connected, we did rejig the comms chip to get one that was less supply chain constraints. So, those two are reengineering back in the line. We didn't reengineer the AirSense 11 that's selling right now. But of course, there will be variance. This is a long-term platform. This platform, the AirSense 11 is going to do CPAP, APAP, bi-level, all sorts of amazing therapy models. If you even look at the work that we're doing on the Lumis HFT device that we talked about earlier in the Q&A and during my prep remarks, that's on a platform of the AirSense 10 and obviously, AirSense 11 will become the platform of note for us over the coming years. But we don't go into details of our future product pipeline. So, thanks for the question. But look, I can tell you, those three products in the market are number one, two, and three and as you saw this quarter, they're selling well, and we expect them to continue to.

Thank you. Next question is from Lyanne Harrison from Bank of America. Your line is now live.

Good morning all. I might just come back to that full customer demand comment by the end of calendar 2023. Mick, is that in relation to just the new starts? Or do you also expect that you'll meet the demand for the backlog of RePAPs as well that we've had over the last few years?

Yes, Lyanne, you're getting to some of the complexities behind that. Look, our goal is to get off the supply constraint during this calendar and we know we can get there. We won't get there if we turn on every single knob that we have for demand generation and RePAP generation around the world. And so we will be turning those dials, if you like, for demand generation and RePAP generation through our customers and directly as we get supply improving country-by-country. And so yes, I think we can get to all customer demand if we do no change faster, but our goal is to take care of not just the patients who are currently in the pipeline, but also the 80% -- 90% in many countries who are undiagnosed and untreated. And so our mission is to do that and it's aligned with altruism but also our profit motive. And the overlap of those is a really powerful tool for us to have sustainable long-term growth as we have the last 33.5 years. And so clearly, if we turn every dial to max, we wouldn't be able to get off a constraint this year. We won't turn all to max, but we will and we are starting to turn those dials and getting the programs up and running in different cities, different states, different geographies around the world as we start to get off-constraint. So, I won't go into further detail than that to say that, Lyanne, yes, you're digging in, it is more complex than just we get there. It's we get there and then we start turning on the market growth rate as the market leader, which is our sort of our duty and our obligation and we're going to do both. We're going to grow the market and grow our share and deliver for patients.

Thank you. Our final question today is coming from Steve Wheen, it’s a follow-up from Jarden. Please go ahead.

Yes, thanks for taking my question. This question is about the diagnosis rate in the US, in particular, for OSA. There has been some frustration to the ability to diagnose patients. So, I just wonder what you're seeing from -- during the quarter from an improvement on that front with regard to diagnosis?

Yes, Steve, thanks and thanks for coming for your second question at the end of the queue. It shows that the system works and you can get the second question in. It's a good one. Our diagnosis rate in the US, obviously, impacted the start of COVID with all the labs being shut down and then we saw that big pivot and adoption of home sleep apnea testing and some great models from ResMed and many other players in the market to help physicians find ways to remotely screen, diagnose, treat, and manage sleep apnea patients. As we come out from pandemic to endemic in the US, we've definitely seen -- I'd say, our data show that at least 50% of patients are going through home sleep apnea testing. And then of the other 50%, some of them do home sleep apnea test and then just a follow-up in a lab for titration and mask fit and so on. And so really good adoption of home sleep apnea testing. It's sort of related to our demand generation area that demand generation isn't just going out there on social media and advertising and finding that customer acquisition cost and appropriate place well under lifetime value and getting them into the channel. It's also working with the channel to understand where we have capacity, what cities, what geographies that we have. And as you know, Steve following us closely, we purchased a company called Ectosense, and their product called NightOwl. And I have one sitting on the desk right here. This thing is the size of my fingertip and it has the ability to have highly sensitive and specific screening and diagnosis of sleep apnea with reimbursement in a geography like the US, and we're actually experimenting in Asia and Latin America and around the world on this. And the technology is originally European, so hopefully, it gets adopted there, too. I love Ectosense, and I love home sleep apnea testing happening where it's small, it's quiet, it's convenient, and its cloud connected similar to our therapeutics. And yes, so I think you're going to see that diagnostic rate in the US pick up post-pandemic because people learned that telemedicine, digital health, remote screening, remote diagnostics work, and we can scale them. But it won't just be here in the US. It might be pioneered, launched here, and scaled here. but it's going to work in many other countries around the world. And I can tell you we're really excited about partnerships with the physicians and the patients themselves to find their path to better sleep and better breathing. Thanks for the question.

Thank you. We reached the end of our question-and-answer session. I'd like to turn the floor back over to Mick for any further or closing comments.

Thanks Kevin and thank you again to all of our shareholders and stakeholders for joining us on this call. I'd want to thank once again the opportunity for all 10,000 ResMedians, many of whom of you are also shareholders. So, thank you for that. Thank you also for your dedication, hard work, helping people breathe, sleep, and live better lives in over 140 countries. You delivered these numbers. Thank you for all that you do. And I'll hand back to you, Amy.

Great. Thank you, Mick and thanks everyone for joining us. We appreciate your interest and your time. And as always, if you have any additional questions or need to follow-up, please don't hesitate to reach out directly. This does conclude ResMed's second quarter 2023 conference call. Kevin, I'll turn it back to you to close things out.

Thank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.